Integer Holdings (ITGR) AI Stock Analysis

• Market Cap: $3.62B
• Dividend Yield: N/A
• Average Volume (3M): 346.33K
• Price to Earnings (P/E): 45.6
• Beta (1Y): 0.70
• Revenue Growth: 7.21%
• EPS Growth: -23.29%
• Country: US
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 1.55
• Shares Outstanding: 35,034,817
• 10 Day Avg. Volume: 495,007
• 30 Day Avg. Volume: 346,326
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.57
• Enterprise Value/Revenue: 3.16
• Enterprise Value/Gross Profit: 11.75
• Enterprise Value/Ebitda: 22.16
• 1Y Price Target: $136.00
• Price Target Upside: 31.64% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 65 Neutral
• Price Target: $116.00 ▲(12.28% Upside)

Integer Holdings' overall score is driven by strong financial performance and positive earnings outlook. However, the technical analysis suggests bearish momentum, and the high P/E ratio indicates valuation concerns. Positive corporate events add to the company's prospects, but market sentiment remains cautious.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Cash Flow Strength

Strong cash flow growth enhances financial flexibility, enabling strategic investments and reducing reliance on external financing.

Strategic Board Expansion

Adding experienced leadership can drive strategic initiatives and enhance competitive positioning in the medical device industry.

Negative Factors

Profit Margin Decline

Declining profit margins may indicate cost control challenges, potentially impacting long-term profitability and shareholder returns.

CRM & Neuromodulation Growth Concerns

Slow growth in key segments could hinder overall revenue expansion and market competitiveness, affecting future performance.

Top-End Revenue Guidance Narrowed

Narrowing revenue guidance suggests potential challenges in sustaining growth, which could impact investor confidence and strategic planning.

Integer Holdings Business Overview & Revenue Model

Company Description

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

How the Company Makes Money

Integer Holdings generates revenue through the sale of its medical devices and implants across various healthcare sectors. Its primary revenue streams include direct sales of cardiac and neuromodulation devices, orthopedic implants, and related accessories. The company often partners with healthcare providers, hospitals, and distributors to expand its market reach. Additionally, Integer invests in research and development to innovate and improve its product offerings, which helps to maintain a competitive edge and secure long-term contracts with healthcare organizations. Moreover, strategic collaborations and acquisitions within the medical device market further bolster its revenue potential.

Integer Holdings Financial Statement Overview

Summary

Integer Holdings demonstrates strong revenue growth and operational efficiency. The balance sheet is stable but could improve in shareholder returns. Cash flow is robust with significant free cash flow improvements, indicating strong liquidity.

Income Statement

Integer Holdings shows a strong revenue growth trajectory, with Total Revenue increasing from $1.37 billion in 2022 to $1.79 billion in TTM (Trailing-Twelve-Months). Gross Profit Margin stands at 26.9% for TTM, indicating improved profitability. However, Net Profit Margin decreased to 4.6% in TTM from 7% in 2024, suggesting challenges in controlling costs. The EBIT and EBITDA margins are stable, showcasing efficient operational performance.

Balance Sheet

The balance sheet reflects a moderate financial structure with a Debt-to-Equity Ratio of 0.78 in TTM, indicating a balanced leverage position. The Equity Ratio is stable at 50.5%, suggesting healthy equity levels relative to assets. However, the Return on Equity (ROE) declined to 4.9% in TTM, highlighting reduced profitability for shareholders.

Cash Flow

Operating Cash Flow remains robust at $209.9 million for TTM, with a favorable Operating Cash Flow to Net Income Ratio of 2.54. Free Cash Flow grew significantly by 65% from 2024 to TTM, indicating strong cash generation capacity. However, Free Cash Flow to Net Income Ratio at 1.99 shows potential to improve net earnings conversion into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.79B	1.72B	1.60B	1.38B	1.22B	1.07B
Gross Profit	482.83M	459.01M	418.29M	359.01M	336.97M	285.71M
EBITDA	256.11M	310.91M	256.51M	215.40M	215.26M	207.56M
Net Income	82.66M	119.90M	90.65M	66.38M	96.81M	77.26M
Balance Sheet
Total Assets	3.37B	3.08B	2.94B	2.79B	2.58B	2.37B
Cash, Cash Equivalents and Short-Term Investments	23.14M	46.54M	23.67M	24.27M	17.89M	49.21M
Total Debt	1.32B	1.10B	1.05B	1.01B	897.75M	777.55M
Total Liabilities	1.67B	1.46B	1.42B	1.38B	1.23B	1.10B
Stockholders Equity	1.70B	1.62B	1.52B	1.42B	1.35B	1.27B
Cash Flow
Free Cash Flow	164.51M	99.60M	60.27M	41.65M	103.20M	129.90M
Operating Cash Flow	209.87M	205.21M	180.21M	116.38M	156.67M	181.34M
Investing Cash Flow	-211.61M	-195.41M	-163.37M	-200.42M	-271.00M	-56.58M
Financing Cash Flow	-9.46M	13.32M	-18.01M	92.48M	81.99M	-88.58M

Integer Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 103.31
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ITGR, the sentiment is Negative. The current price of 103.31 is below the 20-day moving average (MA) of 105.53, below the 50-day MA of 108.08, and below the 200-day MA of 121.88, indicating a bearish trend. The MACD of -1.65 indicates Positive momentum. The RSI at 43.22 is Neutral, neither overbought nor oversold. The STOCH value of 47.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ITGR.

Integer Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IRTC	66 Neutral	5.62B	-59.61	-89.17%	―	22.37%	31.14%
ITGR	65 Neutral	$3.62B	45.62	5.15%	―	7.21%	-23.29%
LIVN	61 Neutral	3.00B	-14.13	-18.82%	―	8.57%	-1154.64%
INSP	58 Neutral	2.36B	46.28	7.84%	―	22.05%	785.52%
GKOS	52 Neutral	4.79B	-50.37	-12.13%	―	26.70%	48.19%
PRCT	50 Neutral	2.08B	-24.01	-21.81%	―	55.71%	24.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Integer Holdings Corporate Events

Integer Holdings Reports Strong Q2 2025 Financial Results

Integer Holdings Corporation reported strong financial results for the second quarter of 2025, with sales increasing by 11% to $476 million and adjusted operating income rising by 15% to $81 million compared to the same period in 2024. The company also raised its full-year profit outlook, expecting adjusted operating income growth of 12% to 16% and adjusted EPS growth of 18% to 23%, driven by robust sales in cardio and vascular segments and strategic acquisitions.

The most recent analyst rating on (ITGR) stock is a Buy with a $152.00 price target. To see the full list of analyst forecasts on Integer Holdings stock, see the ITGR Stock Forecast page.

Integer Holdings Expands Board with Michael J. Coyle

On July 10, 2025, Integer Holdings Corporation announced the election of Michael J. Coyle to its Board of Directors, expanding the board to 11 members. Coyle, with over 40 years of leadership experience in the medical device industry, will serve on several committees and contribute to Integer’s strategic initiatives and growth. His extensive background, including roles at iRhythm Technologies and Medtronic, is expected to bolster Integer’s position as a partner of choice for innovative medical technologies, enhancing its contract development and manufacturing outsourcing strategy.

The most recent analyst rating on (ITGR) stock is a Buy with a $135.00 price target. To see the full list of analyst forecasts on Integer Holdings stock, see the ITGR Stock Forecast page.

Integer Holdings Announces Convertible Notes Conversion Option

On July 2, 2025, Integer Holdings Corporation announced that its 2.125% Convertible Senior Notes due 2028 are now convertible at the holders’ option during the calendar quarter ending September 30, 2025. This conversion option was triggered as the company’s stock price exceeded 130% of the conversion price for at least 20 trading days in a 30-day period ending June 30, 2025. The notes can be converted into cash, shares of common stock, or a combination thereof, depending on the company’s choice. This announcement could impact the company’s financial strategy and market positioning, as it allows note holders to convert their notes into equity, potentially affecting the company’s stock liquidity and capital structure.

The most recent analyst rating on (ITGR) stock is a Buy with a $152.00 price target. To see the full list of analyst forecasts on Integer Holdings stock, see the ITGR Stock Forecast page.

Integer Holdings Stockholders Approve Key Proposals at Annual Meeting

At the Annual Meeting on May 21, 2025, Integer Holdings‘ stockholders approved several key proposals. These included the election of ten directors for a one-year term, the ratification of Deloitte & Touche LLP as the independent auditors for fiscal year 2025, approval of executive compensation on an advisory basis, and an amendment to the company’s Restated Certificate of Incorporation to include an officer exculpation provision. These decisions are expected to impact the company’s governance and operational strategies moving forward.

The most recent analyst rating on (ITGR) stock is a Buy with a $152.00 price target. To see the full list of analyst forecasts on Integer Holdings stock, see the ITGR Stock Forecast page.